Posted in | Pharmaceuticals and Drug Discovery

Exploring CK1 degrader discovery and molecular glue technologies

From Sep 20 2025

Pharmaron presents Part 2 of its molecular glues on-demand webinar series, bringing together leading experts in drug discovery for a deep dive into case studies. This session will focus on the biological insights and novel chemical strategies that enabled the progression from early hits to clinical candidates.

Attendees will gain practical takeaways to support their own research in the fast-evolving field of molecular glue degraders.

For those seeking a foundational understanding of the topic, Part 1 is available on demand, providing an introduction to the key concepts and mechanisms underlying targeted protein degradation.

What the webinar covers:

  • Discovery of a CK1α degrader
  • Key insights from new hit-finding assays for molecular glues
  • Future perspectives and emerging technologies in targeted protein degradation

About the speakers

  • Bora Lee – Head of Business Development at Pin Therapeutics
  • Maxime Couturier – Senior Research Scientist at AstraZeneca
  • Chris Wellaway – Associate Director, Medicinal Chemistry, Drug Discovery at Pharmaron
  • Moderated by Amy Brown - Biologist, Drug Discovery Services at Pharmaron

Other Webinars from Pharmaron

Key considerations for dosimetry from non clinical to clinical application

Key considerations for dosimetry from non clinical to clinical application
Scaling up API production: How to balance speed with supply chain security

Scaling up API production: How to balance speed with supply chain security
The principles of macrocyclic drug discovery

The principles of macrocyclic drug discovery
Smarter drug design with molecular glues

Smarter drug design with molecular glues
Practical in vitro insights into low clearance compounds

Practical in vitro insights into low clearance compounds
Advancing hADME with modern AMS tools

Advancing hADME with modern AMS tools
Data-driven or physics-based: Choosing the smarter approach to DMPK modeling

Data-driven or physics-based: Choosing the smarter approach to DMPK modeling
What’s changing in DDI guidance? A closer look at ICH M12

What’s changing in DDI guidance? A closer look at ICH M12
Enhancing assay precision for small molecule bioanalysis

Enhancing assay precision for small molecule bioanalysis
Strategies for the successful development of antibody drug conjugates

Strategies for the successful development of antibody drug conjugates
Key ADME and DMPK insights for oligonucleotide drug development

Key ADME and DMPK insights for oligonucleotide drug development

Life Science Webinars by Subject Matter

Watch the
Webinar

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback